Paper39347697
Cardiac Myosin Inhibition in Heart Failure With Normal and Supranormal Ejection Fraction: Primary Results of the EMBARK-HFpEF Trial.
Shah SJ and 11 others. JAMA Cardiol, 2025. Cited by 34 papers, by iCite.
Cite this record
ConductScience Library. Cardiac Myosin Inhibition in Heart Failure With Normal and Supranormal Ejection Fraction: Primary Results of the EMBARK-HFpEF Trial. Papers, record 39347697. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39347697
- Disease
- heart failure311 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Cardiac Myosin Inhibition in Heart Failure With Normal and Supranormal Ejection Fraction: Primary Results of the EMBARK-HFpEF Trial.
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cardiac Myosins | Major topic |
| Heart Failure | Major topic |
| Stroke Volume | Major topic |
| Uracil | Major topic |
| Aged | |
| Aged, 80 and over | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Echocardiography | |
| Natriuretic Peptide, Brain | |
| Peptide Fragments | |
| Treatment Outcome | |
| Ventricular Function, Left | |
| Proof of Concept Study | |
| Benzylamines |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| U54HL160273 | NIH |
Source NIH RePORTER
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT04766892 | A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT | Derived from the trial | Yes |
Source ClinicalTrials.gov
References15
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21440868 | Decreased cardiac functional reserve in heart failure with preserved systolic function. | J Card Fail | 2011 | https://conductscience.org/library/papers/21440868 | PubMed |
| 2 | 31386109 | Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie? | Eur Heart J | 2020 | https://conductscience.org/library/papers/31386109 | PubMed |
| 3 | 36994635 | Ventricular stiffening and chamber contracture in heart failure with higher ejection fraction. | Eur J Heart Fail | 2023 | https://conductscience.org/library/papers/36994635 | PubMed |
| 4 | 36029466 | DELIVERing Therapeutic Efficacy Across the Ejection Fraction Spectrum of Heart Failure. | Circulation | 2022 | https://conductscience.org/library/papers/36029466 | PubMed |
| 5 | 32871100 | Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet | 2020 | https://conductscience.org/library/papers/32871100 | PubMed |
| 6 | 16487838 | B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. | J Am Coll Cardiol | 2006 | https://conductscience.org/library/papers/16487838 | PubMed |
| 7 | 35502770 | Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter. | J Am Heart Assoc | 2022 | https://conductscience.org/library/papers/35502770 | PubMed |
| 8 | 37804245 | Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. | Eur Heart J | 2023 | https://conductscience.org/library/papers/37804245 | PubMed |
| 9 | 35862208 | Characteristics of Heart Failure With Preserved Ejection Fraction Across the Range of Left Ventricular Ejection Fraction. | Circulation | 2022 | https://conductscience.org/library/papers/35862208 | PubMed |
| 10 | 33750209 | Exploring New and Old Therapies for Obstructive Hypertrophic Cardiomyopathy: Mavacamten in Perspective. | Circulation | 2021 | https://conductscience.org/library/papers/33750209 | PubMed |
| 11 | 17707182 | Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. | J Am Coll Cardiol | 2007 | https://conductscience.org/library/papers/17707182 | PubMed |
| 12 | 37191180 | Prevalence, characteristics and cardiovascular and non-cardiovascular outcomes in patients with heart failure with supra-normal ejection fraction: Insight from the JROADHF study. | Eur J Heart Fail | 2023 | https://conductscience.org/library/papers/37191180 | PubMed |
| 13 | 32466879 | Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy. | J Am Coll Cardiol | 2020 | https://conductscience.org/library/papers/32466879 | PubMed |
| 14 | 24184245 | Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. | J Am Coll Cardiol | 2014 | https://conductscience.org/library/papers/24184245 | PubMed |
| 15 | 35435607 | The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review. | Am J Cardiovasc Drugs | 2022 | https://conductscience.org/library/papers/35435607 | PubMed |
Cited by26
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 34 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42814187 | Complication management in hypertrophic cardiomyopathy. | Heart Fail Rev | 2026 | https://conductscience.org/library/papers/42814187 | PubMed |
| 42781371 | Coronary microvascular dysfunction in HFpEF: pathophysiologic mechanisms, diagnosis, treatments, and the amplifying potential of sepsis. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42781371 | PubMed |
| 42762037 | Heart Failure with Reduced versus Preserved Ejection Fraction: Molecular Mechanisms, Immunologic Pathways, Current Therapies, and Future Directions. | Arch Intern Med Res | 2026 | https://conductscience.org/library/papers/42762037 | PubMed |
| 42591999 | Mitochondrial-inflammatory coupling in HFpEF: an emerging mechanistic framework for understanding the cardioprotective effects of SGLT2 inhibitors. | Front Cardiovasc Med | 2026 | https://conductscience.org/library/papers/42591999 | PubMed |
| 42362932 | Myofilament-level effects of aficamten increase diastolic chamber volumes and maintain cardiac output through preserved length-dependent force generation in healthy rat and canine myocardium. | Basic Res Cardiol | 2026 | https://conductscience.org/library/papers/42362932 | PubMed |
| 42182770 | Heart failure in 2025: new insights, therapies, and clinical directions. | J Thorac Dis | 2026 | https://conductscience.org/library/papers/42182770 | PubMed |
| 42024776 | Severe obesity in human HFpEF alters contractile protein function and organization. | Science | 2026 | https://conductscience.org/library/papers/42024776 | PubMed |
| 41659088 | Targeting the Sarcomere: Myosin Inhibitors as the Revolutionary Game Changer in Hypertrophic Cardiomyopathy. | Rev Cardiovasc Med | 2026 | https://conductscience.org/library/papers/41659088 | PubMed |
| 41528064 | Anthracycline cardiotoxicity: role of metabolic vulnerability induced by cardiac pressure overload. | Eur Heart J | 2026 | https://conductscience.org/library/papers/41528064 | PubMed |
| 41497974 | NEW TREATMENTS FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION. | Ulster Med J | 2025 | https://conductscience.org/library/papers/41497974 | PubMed |
| 41324783 | Mavacamten in the Treatment of Obstructive Hypertrophic Cardiomyopathy: from Pathophysiology To Real World Data. | Curr Cardiol Rep | 2025 | https://conductscience.org/library/papers/41324783 | PubMed |
| 41127363 | Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: Clinical Advances and Therapeutic Prospects. | Drug Des Devel Ther | 2025 | https://conductscience.org/library/papers/41127363 | PubMed |
| 40977229 | Deep phenotyping of heart failure with preserved ejection fraction through multi-omics integration. | Eur J Heart Fail | 2025 | https://conductscience.org/library/papers/40977229 | PubMed |
| 40890312 | Beta blockers linked to reduced 1-Year mortality in critically ill congestive heart failure patients with differential benefits across subgroups. | Sci Rep | 2025 | https://conductscience.org/library/papers/40890312 | PubMed |
| 40869375 | Novel Drug Targets in Diastolic Heart Disease. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40869375 | PubMed |
| 40867543 | Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: Clinical Trials and Future Challenges. | Biomolecules | 2025 | https://conductscience.org/library/papers/40867543 | PubMed |
| 40807027 | Current Treatment of Heart Failure with Preserved Ejection Fraction. | J Clin Med | 2025 | https://conductscience.org/library/papers/40807027 | PubMed |
| 40722692 | Comprehensive Review: Mavacamten and Aficamten in Hypertrophic Cardiomyopathy. | Biomedicines | 2025 | https://conductscience.org/library/papers/40722692 | PubMed |
| 40624601 | Cardiac myosin inhibitors in hypertrophic cardiomyopathy. | J Cardiovasc Imaging | 2025 | https://conductscience.org/library/papers/40624601 | PubMed |
| 40584916 | Pathophysiological and prognostic relevance of exercise CMR-derived pulmonary artery compliance in patients with suspected diastolic dysfunction and normal right ventricular function. | Eur Heart J Imaging Methods Pract | 2025 | https://conductscience.org/library/papers/40584916 | PubMed |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| MAVACAMTEN | CHEMBL4297517 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL4297517 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39347697
GET https://conductscience.org/api/papers/v1/39347697/cited_by?page=2